Recent news regarding pharma companies in Asia
This Cardiogram work was based on Framingham Heart Study 2015, where the resting and variable heart rate significantly predicted hypertension and diabetes. This prototype helped the cardiogram research team to use the Apple Watch’s heart rate sensor for accurate diabetes predictions.
General Electric (GE) has a new spinoff with great potential in the healthcare sector, as a separate standalone firm. This would enable great opportunities for growth and innovation.
Scientists from the University of Texas have developed a way to sense dangerous chemicals, a basic model consisting of a smartphone and a box made from Lego bricks, which could help scientists to identify deadly and difficult-to-detect nerve agents such as sarin and VX. The new approach combines a chemical sensor with photography to notice and recognize different nerve agents.
Switzerland-based NBE Therapeutics AG, a biopharmaceutical company, announced a $20 million extension of series B funding led by Novo Holdings. Earlier in the series B funding round, the company had received $20 million, bringing the total funding to $40 million. The Swiss startup will use the new funding for the testing of the anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in patients with solid tumors.
This keychain-sized portable allergen detector is called an Integrated Exogenous Antigen Testing System (IEAT). By placing a drop or a bit of food on a single use slide namely an ‘antigen extraction device’, it can detect the allergen and its quantity within 10 minutes by performing necessary chemical deconstruction.
According to the WHO statistical report, around 1.5 million deaths are caused due to diabetes worldwide. With these statistics in mind, a research team from the University of Copenhagen and Aarhus University in Denmark conducted research on diabetes patients.
The San Diego-based biotech company Crinetics Therapeutics recently raised $86 million in an IPO. Prior to the new funding, the company received $63.5 million in series B funding and will see its lead asset through phase 2.
The inject is developed to achieve the natural outflow of aqueous humor by making two patent bypasses through the trabecular meshwork, glaucomatous eyes the main source of resistance resulting in multi-directional flow through Schlemm’s canal
Keytruda is now allowed only for the patients whose tumor expression levels of the biomarker PD-L1 meet a combined positive score of 10 or higher. Tecentriq can only be used where PD-L1 immune cells can cover only 5% or more of their tumor area.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.